Ask AI
PulseCast Multiple Myeloma ASH 2025
PulseCast: Highlights in Multiple Myeloma From the 2025 ASH Annual Meeting

Released: December 23, 2025

Activity

In this episode, Shaji K. Kumar, MD, reviews key highlights from ASH 2025 in multiple myeloma (MM), focusing on emerging data for bispecific antibodies and CAR T-cell therapies across earlier and later lines of treatment. The discussion covers the following:

  • MajesTEC-3: Results from the phase III study of teclistamab + daratumumab in R/R MM
  • RedirecTT-1: Updated efficacy and safety of talquetamab + teclistamab in R/R MM and extramedullary disease
  • CARTITUDE-4: Results following treatment with cilta-cel in patients with standard-risk cytogenetics
  • STEM: Preliminary safety and efficacy data from the phase II study of cevostamab consolidation following BCMA-directed CAR T-cell therapy
  • CAMMA1: Biomarker analyses from Arm B following cevostamab + pomalidomide and dexamethasone treatment in patients with R/R MM